GB2597313A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

USPTO Abstract

The present invention relates to the use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and a mutation in the DEPDC5 gene which encodes a protein that is part of the GATOR1 complex. In a further embodiment the types of seizures include tonic, tonic-clonic, and focal seizures without impairment. Preferably the CBD comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including vigabatrin or carbamazepine. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. Preferably the CBD used is in the form of a botanically derived purified CBD, but a synthetically produced CBD can alternatively be used. A method of treating seizures with CBD is also disclosed.